M‐CAM expression as marker of poor prognosis in epithelial ovarian cancer

Aldovini, D; Demichelis, Francesca; Doglioni, Claudio; Vizio, Dolores Di; Galligioni, Enzo; Brugnara, S.; Zeni, B.; Griso, C.; Pegoraro, C.; Zannoni, M; Gariboldi, Manuela; Balladore, Emanuela; Mezzanzanica, Delia; Canevari, Silvana; Barbareschi, Mattia

doi:10.1002/ijc.22082

Cited by 74 publications

(75 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several lines of evidence suggested that CD146 expression is upregulated in various types of experimental and clinical tumors, including melanoma (Shih et al, 1994;Johnson et al, 1997), prostate cancer (Wu et al, 2001(Wu et al, , 2004, epithelial ovarian cancer (Aldovini et al, 2006), non-small-cell lung cancer (Kristiansen et al, 2003) and mesothelioma (Bidlingmaier et al, 2009). More importantly, ectopic expression of CD146 in melanoma was found in a positive correlation with tumorigenic transformation and the development of metastatic potential in both mice models and clinical data (Luca et al, 1993;Li et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration

et al. 2011

View full text Add to dashboard Cite

Tumor cell migration is a well-orchestrated multistep process that drives cancer development and metastasis. Previous data indicated that CD146 expression correlates with malignant progression and metastatic potential of human melanoma cells. However, the exact molecular mechanism of how CD146 promotes melanoma cell migration still remains poorly understood. Here, we report that CD146 physically interacts with actin-linking ezrin-radixin-moesin (ERM) proteins and recruits ERM proteins to cell protrusions, promoting the formation and elongation of microvilli. Moreover, CD146-promoted melanoma cell migration is linked to RhoA activation and ERM phosphorylation. CD146 recruits Rho guanine nucleotide dissociation inhibitory factors 1 (RhoGDI1) through ERM proteins and thus sequesters RhoGDI1 from RhoA, which leads to upregulated RhoA activity and increased melanoma cell motility. CD146-activated RhoA also promotes further ERM phosphorylation and activation through Rho-phosphatidylinositol-4-phosphate-5-kinase-phosphatidylinositol 4,5-biphosphate pathway, which reinforces CD146/ERM association. Thus, our results provide a mechanistic basis to understand the role of CD146 in regulating human melanoma cell motility.

show abstract

Section: Introductionmentioning

confidence: 99%

Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration

et al. 2011

View full text Add to dashboard Cite

show abstract

“…21 Increased CD146 expression has been shown to be closely associated with an advanced stage of malignant melanoma, prostate cancer, and ovarian cancer. [21][22][23][24][25] However, the relation between CD146 expression and the malignancy of mesothelioma has not been investigated. The purpose of the present study was to evaluate the utility of CD146 detection for distinguishing malignant pleural mesothelioma and reactive mesothelium in diagnostic cytology.…”

mentioning

confidence: 99%

Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium

et al. 2010

View full text Add to dashboard Cite

Malignant pleural mesothelioma is a refractory tumor with poor prognosis associated with asbestos exposure. Pleural effusion is frequently observed in patients with malignant pleural mesothelioma, and cytological analysis is effective to detect malignant pleural mesothelioma. However, cytological discrimination between malignant pleural mesothelioma and reactive mesothelium is often difficult. Increased expression of CD146, a cell adhesion molecule, has been reported to be closely associated with an advanced stage of malignant melanoma, prostate cancer, and ovarian cancer. In this study, to evaluate the diagnostic utility of CD146 for discrimination between malignant pleural mesothelioma and reactive mesothelium, we examined immunocytochemical expression of CD146 in malignant pleural mesothelioma and reactive mesothelium using two clones of CD146 antibody, OJ79 and EPR3208, on smear specimens of effusion fluids. Immunocytochemical stains were semiquantitatively scored on the basis of immunostaining intensity (0, negative; 1, weak positive; 2, moderate positive; and 3, strong positive). CD146 expression was detected in 15 of 16 malignant pleural mesothelioma with median immunostaining score of 3 by OJ79, and in 19 of 21 malignant pleural mesothelioma with median immunostaining score of 2 by EPR3208. Strong immunoreactivity of CD146 was observed at the apposing surfaces of cell-cell interactions on the plasma membrane of mesothelioma cells. In addition, one OJ79-negative case of malignant pleural mesothelioma was positive for CD146 by EPR3208 and two EPR3208-negative cases of malignant pleural mesothelioma were CD146 positive by OJ79, showing that all 23 malignant pleural mesothelioma cases were positive for CD146 by either OJ79 or EPR3208. On the other hand, CD146 expression was undetectable in all reactive mesothelium cases by OJ79 and EPR3208. The sensitivity of OJ79 and EPR3208 was 94 and 90%, respectively, and the specificity was 100% for both clones. We propose that CD146 is a sensitive and specific immunocytochemical marker enabling differential diagnosis of malignant pleural mesothelioma from reactive mesothelium.

show abstract

“…No immunoreactivity occurred in normal ovarian tissue (original magnification, 25 Â ) (f). UbcH10 immunoreactivity has been evaluated in two TMAs (constructed at the Department of Histopathology, S Chiara Hospital, Trento, Italy), as described (Aldovini et al, 2006). TMAs included 60 carcinomas arising from the ovarian surface epithelium, each represented by three different 0.6 mm cores.…”

mentioning

confidence: 99%

“…Thus, tumors were graded into well differentiated (G1), moderately well differentiated without nuclear atypia (G2), moderately well differentiated with nuclear atypia (G3) and poorly differentiated or undifferentiated (G4) (Vacher-Lavenu et al, 1993). Further details on TMAs generation are reported elsewhere (Aldovini et al, 2006). Complete follow-up data were available for all patients from the Departments of Gynecological Surgery and Medical Oncology of the S Chiara Hospital of Trento.…”

mentioning

confidence: 99%